Biotech · Private company
CTI BioPharma
Track this companyFree. Adds CTI BioPharma to your Dealase workspace and tells you when its record changes.
Clinical trials251 recruiting or active
Pipeline programs35From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline35
- Best Available TherapyPhase 3 · Primary MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
- CT-2103/carboplatinPhase 3 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- fludarabine phosphatePhase 3 · LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Gemcitabine + RituximabPhase 3 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- paclitaxelPhase 3 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- paclitaxel poliglumexPhase 3 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- paclitaxel/carboplatinPhase 3 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- PacritinibPhase 3 · Primary MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
- Pixantrone + RituximabPhase 3 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- pixantrone dimaleatePhase 3 · LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- rituximabPhase 3 · LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- arsenic trioxidePhase 2 · Multiple Myeloma and Plasma Cell NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- arsenic trioxidePhase 2 · LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- chemotherapyPhase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- CHOP-RPhase 2 · Diffuse Large-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- CPOP-RPhase 2 · Diffuse Large-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- CT-2584Phase 2 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- dexamethasonePhase 2 · Multiple Myeloma and Plasma Cell NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- PacritinibPhase 2 · COVID19ClinicalTrials.gov · fetched Nov 12, 2026
- Pixantrone IV infusionPhase 2 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- (Treatment A)Phase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- (Treatment B)Phase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- A: pacritinibPhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- C: moxifloxacinPhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- CHR-2797Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- CYP450 Cocktail and Transporter Substrates with PacritinibPhase 1 · Drug InteractionsClinicalTrials.gov · fetched Nov 12, 2026
- oral dose of 200 mg pacritinib twice daily (BID)Phase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- PacritinibPhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Pacritinib and RifampinPhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with PacritinibPhase 1 · Drug InteractionsClinicalTrials.gov · fetched Nov 12, 2026
- Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with PacritinibPhase 1 · Drug InteractionsClinicalTrials.gov · fetched Nov 12, 2026
- PixantronePhase 1 · Metastatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- RifampinPhase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Treatment A: 400 mg Pacritinib P3CTPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Treatment B: 400 mg of pacritinib FMIPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative NeoplasmsPHASE2 · RECRUITING · started Mar 29, 2023ClinicalTrials.gov NCT04858256 · fetched Nov 12, 2026
- Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male SubjectsPHASE1 · COMPLETED · started Jan 3, 2023ClinicalTrials.gov NCT05657613 · fetched Nov 12, 2026
- Study to Evaluate the Safety, Tolerability, and PK of PacritinibPHASE1 · COMPLETED · started Dec 12, 2022ClinicalTrials.gov NCT05552183 · fetched Nov 12, 2026
- PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without CancerPHASE2 · TERMINATED · started May 22, 2020ClinicalTrials.gov NCT04404361 · fetched Nov 12, 2026
- Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With RuxolitinibPHASE2 · COMPLETED · started Jul 31, 2017ClinicalTrials.gov NCT04884191 · fetched Nov 12, 2026
- A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune SuppressionPHASE1_PHASE2 · COMPLETED · started Jun 8, 2017ClinicalTrials.gov NCT02891603 · fetched Nov 12, 2026
- To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy SubjectsPHASE1 · COMPLETED · started Aug 1, 2015ClinicalTrials.gov NCT02823171 · fetched Nov 12, 2026
- Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy SubjectsPHASE1 · COMPLETED · started Jan 1, 2015ClinicalTrials.gov NCT02808455 · fetched Nov 12, 2026
- Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy SubjectsPHASE1 · COMPLETED · started Jan 1, 2015ClinicalTrials.gov NCT02807116 · fetched Nov 12, 2026
- To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy SubjectsPHASE1 · COMPLETED · started Oct 1, 2014ClinicalTrials.gov NCT02807207 · fetched Nov 12, 2026
- Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and ThrombocytopeniaPHASE3 · TERMINATED · started Feb 1, 2014ClinicalTrials.gov NCT02055781 · fetched Nov 12, 2026
- Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male SubjectsPHASE1 · COMPLETED · started Jun 1, 2012ClinicalTrials.gov NCT01638442 · fetched Nov 12, 2026
- Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic ImpairmentPHASE1 · WITHDRAWN · started May 1, 2012ClinicalTrials.gov NCT01632436 · fetched Nov 12, 2026
- Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell TransplantPHASE3 · COMPLETED · started Apr 20, 2011ClinicalTrials.gov NCT01321541 · fetched Nov 12, 2026
- CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mLPHASE3 · WITHDRAWN · started Sep 1, 2007ClinicalTrials.gov NCT00576225 · fetched Nov 12, 2026
- Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin LymphomaPHASE3 · WITHDRAWN · started Aug 1, 2007ClinicalTrials.gov NCT00551239 · fetched Nov 12, 2026
- Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)PHASE3 · TERMINATED · started Oct 1, 2006ClinicalTrials.gov NCT00384111 · fetched Nov 12, 2026
- Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent LymphomasPHASE2 · COMPLETED · started Jun 1, 2006ClinicalTrials.gov NCT00493467 · fetched Nov 12, 2026
- A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.PHASE3 · TERMINATED · started Dec 1, 2005ClinicalTrials.gov NCT00269828 · fetched Nov 12, 2026
- A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against DoxorubicinPHASE2 · COMPLETED · started Nov 1, 2005ClinicalTrials.gov NCT00268853 · fetched Nov 12, 2026
- Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)PHASE1_PHASE2 · COMPLETED · started Mar 1, 2005ClinicalTrials.gov NCT00106600 · fetched Nov 12, 2026
- Arsenic Trioxide in Treating Patients With Myelodysplastic SyndromesPHASE2 · TERMINATED · started Mar 1, 2001ClinicalTrials.gov NCT00020969 · fetched Nov 12, 2026
- Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple MyelomaPHASE2 · TERMINATED · started Feb 1, 2001ClinicalTrials.gov NCT00017069 · fetched Nov 12, 2026
- Arsenic Trioxide in Treating Patients With Multiple MyelomaPHASE2 · TERMINATED · started Jan 1, 2001ClinicalTrials.gov NCT00017433 · fetched Nov 12, 2026
- CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous TherapyPHASE2 · TERMINATED · started Dec 1, 1998ClinicalTrials.gov NCT00004026 · fetched Nov 12, 2026